ESPERION THERAPEUTICS, INC.
ESPR · NASDAQ
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
Market Data
Price
$2.70
-0.34 (-11.18%)
Market Cap$654M
P/E Ratio—
EPS$—
52W High$4.18
52W Low$0.69
Beta1.18
Data from Finnhub · Updated Mar 11, 2026